FDA Enables Potential Use of Experimental Tekmira Vaccine on Ebola Patients

Written by on August 11, 2014 in Featured on App, Regulation and Policy with 0 Comments

On the 7th of August 2014, Tekmira Pharmaceuticals Announced That the FDA has Allowed Potential Use of Their Experimental Ebola Drug on Infected Patients

On the 7th of August 2014, Tekmira Pharmaceuticals Announced That the FDA has Allowed Potential Use of Their Experimental Ebola Drug on Infected Patients

The FDA has lifted a temporary ‘halt in research’ placed on the Ebola drug that has been developed by Canadian company Tekmira Pharmaceuticals. The lift of this hold means that the experimental drug may potentially be used on people infected with Ebola amidst the current outbreak in West Africa.

The hold, although partially lifted, still remains in part. Tekmira still cannot carry out its intentions for a multi-ascending dose portion of a phase 1 trial in health volunteers.

The rapid development of Ebola treatment candidates across the US and Europe looks to lending itself to a cure in the near future.

Read more about it here: FDA Modifies Tekmira’s TKM-Ebola Clinical Hold to Partial Hold

Tags: , , ,

About the Author

About the Author: As a 4th year student studying Biology with management at Imperial College London, I have a passion for health issues and the microscopic world of bacteria and viruses. I'll be around for a while writing about the cutting edge issues that are shaping the pharmaceutical industry and medical progress around the world. .

Subscribe

If you enjoyed this article, subscribe now to receive more just like it.

Subscribe via RSS Feed Connect on Google Plus Join Our LinkedIn Group Connect on YouTube

Leave a Reply

Your email address will not be published. Required fields are marked *

Top
Geolocation